Publicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (37)

2024

  1. Looking for the ideal medication for heart failure with reduced ejection fraction: a narrative review

    Frontiers in Cardiovascular Medicine, Vol. 11

  2. N-terminal pro-B-type natriuretic peptide post-discharge monitoring in the management of patients with heart failure and preserved ejection fraction – a randomized trial: The NICE study

    European Journal of Heart Failure, Vol. 26, Núm. 4, pp. 776-784

2023

  1. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction

    Scientific Reports, Vol. 13, Núm. 1

  2. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study

    European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360

  3. Making STRONGer the transition phase: personalized GDMT through NT-proBNP monitoring

    European heart journal

  4. Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat

    Patient Preference and Adherence, Vol. 17, pp. 839-849

  5. Personalizing anti-inflammatory therapy in heart failure: A new way

    European Journal of Heart Failure

  6. Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status

    JACC: Heart Failure, Vol. 11, Núm. 11, pp. 1611-1622

2022

  1. Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension

    ESC Heart Failure, Vol. 9, Núm. 4, pp. 2170-2180

  2. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 10, pp. 1816-1826

2021

  1. Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction

    Journal of the American College of Cardiology, Vol. 77, Núm. 14, pp. 1747-1759

  2. Colchicine for the treatment of coronary artery disease

    Trends in Cardiovascular Medicine, Vol. 31, Núm. 8, pp. 497-504

  3. Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence

    Scientific Reports, Vol. 11, Núm. 1

  4. Effect of low-dose colchicine in acute and chronic coronary syndromes: A systematic review and meta-analysis

    European Journal of Clinical Investigation, Vol. 51, Núm. 4

  5. Prevalence and characteristics of clonal hematopoiesis in heart failure

    Revista Espanola de Cardiologia, Vol. 74, Núm. 11, pp. 996-999

  6. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review

    Frontiers in Cardiovascular Medicine, Vol. 8

  7. The pre-HFpEF stage: A new entity that requires proper phenotyping for better management

    European Journal of Preventive Cardiology

2020

  1. Author Correction: Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status (Scientific Reports, (2020), 10, 1, (13553), 10.1038/s41598-020-70454-8)

    Scientific Reports

  2. Expert consensus statement on heart failure with reduced ejection fraction: beyond the guidelines

    Revista Espanola de Cardiologia Suplementos, Vol. 20, Núm. SB, pp. 1-46

  3. Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 4, pp. 313-323